Furestem-CD vs remestemcel-L
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: Allogeneic MSC therapy · full Crohn's Disease pipeline
Furestem-CD
Developed by Kangstem Biotech
NCT02000362 · Phase 1/2 · status unknown
This was an uncontrolled, open-label study with no comparator arm and no randomization, so any remission observed cannot be separated from the disease's natural course or a placebo effect; no results have been posted.
No aligned efficacy figure on record for this race.
remestemcel-L · Ryoncil
Marketed by Mesoblast and partners
NCT00482092 · Phase 3 · completed
The study randomly assigned 330 participants and used quadruple masking with matching placebo, with clinical remission measured by CDAI at 28 days as the primary endpoint. However, no trial results or statistical comparison are posted, so the primary endpoint cannot be judged as met or missed.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Furestem-CD | remestemcel-L |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not posted · NCT00482092 |
| Endoscopic response (induction) | —Not reported | —Not posted · NCT00482092 |
| Clinical remission (maintenance) | —Not reported | —Not posted · NCT00482092 |
| Endoscopic response (maintenance) | —Not reported | —Not posted · NCT00482092 |
Clinical remission (induction)
- Furestem-CD
- —Not reported
- remestemcel-L
- —Not posted · NCT00482092
Endoscopic response (induction)
- Furestem-CD
- —Not reported
- remestemcel-L
- —Not posted · NCT00482092
Clinical remission (maintenance)
- Furestem-CD
- —Not reported
- remestemcel-L
- —Not posted · NCT00482092
Endoscopic response (maintenance)
- Furestem-CD
- —Not reported
- remestemcel-L
- —Not posted · NCT00482092
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Furestem-CD: no structured comparison results are available for Crohn's Disease.
remestemcel-L: no structured comparison results are available for Crohn's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Furestem-CD's landscape · remestemcel-L's landscape